Showing results (331-340 of 406) with videos related to
Sort By:
Pageof 41
Hematology (Amsterdam, Netherlands)|February 26, 2024
Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trialHans Salwender, Niels Weinhold, Axel Benner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2016
Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma NetworkEva Hoster, Andreas Rosenwald, Françoise Berger, et al.Haematologica|April 5, 2015
Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trialMaximilian Merz, Hans Salwender, Mathias Haenel, et al.European Journal of Haematology|April 4, 2017
Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsEMarc-Andrea Baertsch, Jana Schlenzka, Katharina Lisenko, et al.Nature|August 2, 2019
Publisher Correction: Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasionAnna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 9, 2019
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow TransplantationDonal McLornan, Richard Szydlo, Linda Koster, et al.Nature|July 19, 2019
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasionAnna M Paczulla, Kathrin Rothfelder, Simon Raffel, et al.The Lancet. Oncology|September 7, 2013
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialJesus San Miguel, Katja Weisel, Philippe Moreau, et al.The Lancet. Haematology|October 9, 2022
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trialSagar Lonial, Rakesh Popat, Cyrille Hulin, et al.Advances in Therapy|August 6, 2025
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple MyelomaCyrille Touzeau, Brea Lipe, Abdullah M Khan, et al.Pageof 41